Teva Pharmaceutical Industries announced the acquisition of Emalex Biosciences. As part of the deal, Teva will add to its ranks a first-of-its-kind treatment and an orphan drug intended for Tourette syndrome, a move aimed at expanding the company’s pipeline of innovative products that are in advanced stages of development.
The main asset of Emalex is “Ecopipam”, a treatment intended for children suffering from Tourette syndrome. The drug has already been classified by the U.S. Food and Drug Administration as an orphan drug and is on a fast-track approval pathway. The advanced clinical program of the drug focuses on the field of neurology, where there is a particularly high medical need. At Teva, they note that the move aligns with the company’s commercial strengths and is expected to support growth both in the short term and in the long term.
On the financial side, upon closing the deal, Emalex shareholders will receive an immediate payment of 700 million dollars in cash. In addition, the agreement includes the possibility of additional payments of up to 200 million dollars, which are contingent on meeting future commercial milestones and subject to FDA approval. Teva will finance the initial payment from its own resources (cash on hand), and it expects the deal to be completed by the third quarter of 2026, subject to regulatory approvals.
Richard Francis, president and CEO of Teva, referred to the acquisition and said: "This is a clear implementation of our 'Pivot to Growth' strategy: Promoting focused deals and financial efficiency, which expand our pipeline of innovative medicines in advanced stages and our product portfolio for commercialization, while maintaining an uncompromising commitment to patients. There is a real medical need in the field of Tourette syndrome, and families deserve additional treatment options that help control symptoms while reducing side effects. Our deep expertise in neurology places us in an excellent position to advance this first-of-its-kind investigational compound".
Despite the scope of the deal, at Teva they clarify that the company intends to reduce the dilutive impact on profit margins in the short term, and it reaffirms the achievement of its financial targets for 2027.